(NASDAQ: DAWN) Day One Biopharmaceuticals's forecast annual revenue growth rate of 15.77% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Day One Biopharmaceuticals's revenue in 2025 is $187,638,000.On average, 4 Wall Street analysts forecast DAWN's revenue for 2025 to be $14,643,669,142, with the lowest DAWN revenue forecast at $14,270,816,906, and the highest DAWN revenue forecast at $15,032,910,487. On average, 4 Wall Street analysts forecast DAWN's revenue for 2026 to be $20,097,657,414, with the lowest DAWN revenue forecast at $17,528,152,375, and the highest DAWN revenue forecast at $26,897,601,286.
In 2027, DAWN is forecast to generate $29,987,972,705 in revenue, with the lowest revenue forecast at $23,603,390,321 and the highest revenue forecast at $37,355,901,646.